                         SEQUENCE LISTING

<110>  Medtronic, Inc.
       van Antwerp, William
       Manda, VenKatesh R.
       Walsh, Andrew J. L.
       Burnes, John
       Lieu, Hsiao
       Evans, Daron
 
<120>  SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART 
       FAILURE USING CHIMERIC NATRIURETIC PEPTIDES

<130>  P0040527.WOU7-MED20003/PCT

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  22
<212>  PRT
<213>  Homo sapiens


<220>
<221>  DISULFID
<222>  (6)..(22)

<400>  1

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  2
<211>  15
<212>  PRT
<213>  Dendroaspis

<400>  2

Pro Ser Leu Arg Asp Pro Arg Pro Asn Ala Pro Ser Thr Ser Ala 
1               5                   10                  15  


<210>  3
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chimeric natriuretic peptide construct


<220>
<221>  DISULFID
<222>  (6)..(22)

<400>  3

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys Pro Ser Leu Arg Asp Pro Arg Pro Asn Ala 
            20                  25                  30          


Pro Ser Thr Ser Ala 
        35          


<210>  4
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  artificial peptide construct


<220>
<221>  DISULFID
<222>  (11)..(27)

<400>  4

Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr 
            20                  25                  30          


<210>  5
<211>  17
<212>  PRT
<213>  Homo sapiens


<220>
<221>  DISULFID
<222>  (1)..(17)

<400>  5

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly 
1               5                   10                  15      


Cys 
    


<210>  6
<211>  10
<212>  PRT
<213>  Homo sapiens

<400>  6

Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser 
1               5                   10  


<210>  7
<211>  5
<212>  PRT
<213>  Homo sapiens

<400>  7

Asn Ser Phe Arg Tyr 
1               5   


<210>  8
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  artificial peptide construct


<220>
<221>  DISULFID
<222>  (6)..(22)

<400>  8

Gly Leu Ser Lys Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys Pro Ser Leu Arg Asp Pro Arg Pro Asn Ala 
            20                  25                  30          


Pro Ser Thr Ser Ala 
        35          


<210>  9
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  artificial peptide construct


<220>
<221>  DISULFID
<222>  (6)..(22)

<400>  9

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Ser Ser 
1               5                   10                  15      


Ser Ser Gly Leu Gly Cys Pro Ser Leu Arg Asp Pro Arg Pro Asn Ala 
            20                  25                  30          


Pro Ser Thr Ser Ala 
        35          


<210>  10
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  artificial peptide construct


<220>
<221>  DISULFID
<222>  (6)..(22)

<220>
<221>  MISC_FEATURE
<222>  (9)..(10)
<223>  X is selected from Lys, Arg and His

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X is selected from Leu, Ile, Met, Val and Ala

<400>  10

Gly Leu Ser Lys Gly Cys Phe Gly Xaa Xaa Xaa Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys Pro Ser Leu Arg Asp Pro Arg Pro Asn Ala 
            20                  25                  30          


Pro Ser Thr Ser Ala 
        35          


<210>  11
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  artificial peptide construct


<220>
<221>  DISULFID
<222>  (6)..(22)

<220>
<221>  MISC_FEATURE
<222>  (15)..(17)
<223>  X is selected from Ser, Gly, Ala and Thr

<400>  11

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Xaa Xaa 
1               5                   10                  15      


Xaa Ser Gly Leu Gly Cys Pro Ser Leu Arg Asp Pro Arg Pro Asn Ala 
            20                  25                  30          


Pro Ser Thr Ser Ala 
        35          


